PE20021138A1 - Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata - Google Patents
Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostataInfo
- Publication number
- PE20021138A1 PE20021138A1 PE2002000438A PE2002000438A PE20021138A1 PE 20021138 A1 PE20021138 A1 PE 20021138A1 PE 2002000438 A PE2002000438 A PE 2002000438A PE 2002000438 A PE2002000438 A PE 2002000438A PE 20021138 A1 PE20021138 A1 PE 20021138A1
- Authority
- PE
- Peru
- Prior art keywords
- prostate
- diseases
- treatment
- antiprogestines
- compositions
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000002307 prostate Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- -1 4-ACETYLPHENYL Chemical class 0.000 abstract 2
- 230000000708 anti-progestin effect Effects 0.000 abstract 2
- 239000003418 antiprogestin Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01250185 | 2001-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021138A1 true PE20021138A1 (es) | 2003-01-11 |
Family
ID=8181589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000438A PE20021138A1 (es) | 2001-05-25 | 2002-05-24 | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1392399A1 (de) |
| JP (2) | JP2004531561A (de) |
| AR (1) | AR034046A1 (de) |
| PE (1) | PE20021138A1 (de) |
| UY (1) | UY27301A1 (de) |
| WO (1) | WO2002094379A1 (de) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3733478A1 (de) * | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| DE4039561A1 (de) * | 1990-12-07 | 1992-07-09 | Schering Ag | Verwendung von antigestagenen zur herstellung von arzneimitteln |
| DE4318371A1 (de) * | 1993-05-28 | 1994-12-01 | Schering Ag | Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung |
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| EE05259B1 (et) * | 2000-10-18 | 2010-02-15 | Schering Aktiengesellschaft | Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks |
| ATE334683T1 (de) * | 2000-10-18 | 2006-08-15 | Schering Ag | Verwendung von 11beta-(4-acetylphenyl)-17beta- |
-
2002
- 2002-05-21 UY UY27301A patent/UY27301A1/es not_active Application Discontinuation
- 2002-05-24 PE PE2002000438A patent/PE20021138A1/es not_active Application Discontinuation
- 2002-05-24 AR ARP020101934A patent/AR034046A1/es not_active Application Discontinuation
- 2002-05-27 EP EP02745322A patent/EP1392399A1/de not_active Ceased
- 2002-05-27 JP JP2002591093A patent/JP2004531561A/ja active Pending
- 2002-05-27 WO PCT/EP2002/005819 patent/WO2002094379A1/en not_active Ceased
-
2009
- 2009-12-10 JP JP2009280715A patent/JP2010077157A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010077157A (ja) | 2010-04-08 |
| WO2002094379A1 (en) | 2002-11-28 |
| EP1392399A1 (de) | 2004-03-03 |
| AR034046A1 (es) | 2004-01-21 |
| UY27301A1 (es) | 2003-02-28 |
| JP2004531561A (ja) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0415971A (pt) | método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica | |
| UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
| MA26843A1 (fr) | NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
| EA200500149A1 (ru) | Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов | |
| ATE538801T1 (de) | Therapeutische zusammensetzungen mit mindestens einem pyrrolobenzodiazepin-derivat und fludarabin | |
| BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
| BR0210056A (pt) | composições e métodos para tratamento de hiperplasia | |
| BR0108930A (pt) | Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente | |
| CY1113967T1 (el) | Μη-υδατικη φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση περιλαμβανουσα βιταμινη d, κορτικοστεροειδες και ενα συστατικο διαλυτη | |
| DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
| HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
| AR004089A1 (es) | Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante. | |
| ATE382356T1 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
| DK1140198T3 (da) | Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad | |
| DK1328276T3 (da) | Anvendelse af antiprogestiner til profylakse og behandling af hormonafhængige sygdomme | |
| ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| NO20073575L (no) | Farmasoytiske sammensetninger for behandling av cellulitt | |
| GT200000194A (es) | Quimioterapia de combinacion. | |
| BR0315931A (pt) | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica | |
| BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| PE20021138A1 (es) | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |